Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.

"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."

"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.

Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005, Chief Operating Officer in 2006 and acting Chief Executive Officer in September 2008. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in oper
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Quantum Center at Skolkovo) and Mario Ziman (Masaryk ... of Physics in Bratislava, Slovakia) have found a ... through an amplifier and, conversely, when transmitting a ... an article published in the journal Physical ... particles are considered to be the basis of ...
(Date:7/23/2014)... Last year, Formedix celebrated its partnership ... of data management solutions for clinical trials. The company ... electronic data capture (EDC) and clinical data management. Formedix, ... tools added TrialMaster to its Transform for EDC product ... for TrialMaster, is being released this week, in response ...
(Date:7/23/2014)... MOINES, Iowa (PRWEB) July 23, 2014 ... join the business as vice president of Agricultural Biotechnology ... Mendel Biotechnology where he served most recently as president, ... extensive biotechnology and business leadership in the seed and ... Pioneer,” said Paul E. Schickler , president of ...
(Date:7/23/2014)...  Sofinnova Ventures, a Menlo Park ... Sofinnova Venture Partners IX, L.P. at the hard cap ... fund target of $425 million. Sofinnova focuses ... with recent funds, SVP IX will provide capital primarily ... with select investments in earlier stage opportunities. Investments will ...
Breaking Biology Technology:Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2
... The single-atom thick material graphene maintains its high ... step to advancing the material from a laboratory phenomenon ... devices, researchers report in the April 9 issue of ... engineers and theoretical physicists from the University of Texas ...
... Mechanical Engineering at Stevens Institute of Technology was named ... (YIP) award by the Office of Naval Research (ONR). ... exceptional promise for creative study. "We are proud ... said ONR,s Director of Research Dr. Michael Kassner. "Through ...
... ... Regulatory Submissions , ... Rockville, MD (Vocus) April 8, 2010 -- Bringing its popular interactive workshop to Europe ... eCTD Submissions in Brussels, 5–7 May. This introductory workshop guides participants on how to ...
Cached Biology Technology:With support, graphene still a superior thermal conductor 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 2Dr. Chang-Hwan Choi honored with prestigious Young Investigator Award 3RAPS to Host eCTD Submissions Workshop in Brussels 2RAPS to Host eCTD Submissions Workshop in Brussels 3
(Date:7/23/2014)... the world have no access to clean drinking water. ... people die from water-related diseases every year. ETH student ... contribution to solving this problem. Working with researchers from ... Functional Materials Laboratory, the 23-year-old spent a year researching ... makes our DrinkPure filter unique is that you can ...
(Date:7/23/2014)... personalized cancer medicine, (the WIN consortium), recently announced that ... University will be one of its six new ... in the Tri-State Area. The goal of WIN is ... the patient by forging collaborations between partners in academia, ... WIN consortium means Jefferson cancer patients will have access ...
(Date:7/23/2014)... potential for clinical use of induced pluripotent stem ... previously been hindered by the risk of dysregulated ... ability to use etoposide treatment to halt teratoma ... disease, specifically acute myocardial infarction, is demonstrated in ... , a peer-reviewed journal from Mary Ann Liebert, ...
Breaking Biology News(10 mins):ETH student develops filter for clean water around the world 2New partnership brings more personalized cancer treatment to Philadelphia 2
... research professor and professor emeritus at The University of ... the American Academy of Arts & Sciences (AAAS), along ... Earl Jones, U.S. Secretary of Defense Robert Gates and ... scientist who translates his discoveries into technology that helps ...
... New York Sea Grant (NYSG) announces the release of ... Populations in South Shore Bays of Long Island, NY, ... of five research projects funded through NYSG,s Hard Clam ... NOAA National Marine Fisheries Service, South Shore Estuary Reserve, ...
... In Maine, government scientists have figured out how to measure ... and the sun - all the while saving money, energy, ... this energy-efficient ingenuity was the need to help the National ... spring snowmelt. The problem was this: While the USGS ...
Cached Biology News:University of Texas at Austin engineer elected to American Academy of Arts and Sciences 2University of Texas at Austin engineer elected to American Academy of Arts and Sciences 3Sea Grant report synthesizes recent research on New York's clams 2Measuring snow with a bucket, a windmill, and the sun? 2
... Expansion Kit - Neurosphere is a system designed ... expansion as neurospheres in a serum free environment. ... Media Supplement, which has been optimized for neural ... . (1996) Genes & Development 10 :3129). ...
Request Info...
... RQ1 RNase-Free DNase is a ... single-stranded or double-stranded DNA to produce ... for use in applications where maintaining ... RQ1 DNase is qualified for use ...
... Polymerase I catalyzes the template-directed polymerization of ... direction. DNA Polymerase I possesses a 3?5 ... the error rate during DNA replication, and ... enables the enzyme to replace nucleotides in ...
Biology Products: